Baird Medical Investment Receives Nasdaq Minimum Bid Price Deficiency Notice
Baird Medical Investment (BDMD) has been notified by Nasdaq of its non-compliance with the exchange's minimum bid price requirement. The notification, dated November 2, 2026, indicates that the company's stock has fallen below the mandatory $1.00 threshold. The company has a 180-day grace period to regain compliance, which extends until May 3, 2027. To avoid potential delisting, Baird Medical must implement strategies to raise its share price above the required minimum within this timeframe.
Topics: delisting warning minimum bid price Nasdaq compliance
Read the full article at Seeking Alpha
Part of the story Baird Medical Investment Receives Nasdaq Minimum Bid Price Deficiency Notice (3 articles)